REVB Q3 2022 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

REVBRevelation Biosciences, Inc.

$2M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$6,262

Operating Income

-$1M

Net Income

-$1M

EPS (Diluted)

$-934.08

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$40,675

Balance Sheet

Total Assets

$7M

Total Liabilities

$4M

Stockholders' Equity

$2M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$6,262	-$20,416	+69.3%
Operating Income	-$1M	-$3M	+60.6%
Net Income	-$1M	-$3M	+61.5%